Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ming-Chu Chang

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Nature Communications|February 13, 2026
PanMETAI - a high performance tabular foundation model for accurate pancreatic cancer diagnosis via NMR metabolomicsDan-Ni Wu, Joey Jen, Erickson Fajiculay, et al.
Journal of Gastroenterology and Hepatology|May 18, 2006
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancerHui-Ju Ch'ang, Chuan-Cheng Wang, Ann-Lii Cheng, et al.
American Journal of Cancer Research|January 22, 2019
Cellular 5-hydroxylmethylcytosine content determines tumorigenic potential and prognosis of pancreatic ductal adenocarcinomaYi-Lng Chen, Chun-Mei Hu, Jeh-Ting Hsu, et al.
Cancer Chemotherapy and Pharmacology|March 26, 2009
Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancerHui-Ju Ch'ang, Chin-Lun Huang, Hsiu-Po Wang, et al.
Clinical Chemistry|February 11, 2016
Clinical Significance of Circulating Tumor Microemboli as a Prognostic Marker in Patients with Pancreatic Ductal AdenocarcinomaMing-Chu Chang, Yu-Ting Chang, Jia-Yang Chen, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|November 15, 2023
Oncogenic KRAS, Mucin 4, and Activin A-Mediated Fibroblast Activation Cooperate for PanIN InitiationChun-Mei Hu, Chien-Chang Huang, Min-Fen Hsu, et al.
Medicine|April 22, 2016
A High Circulating Tumor Cell Count in Portal Vein Predicts Liver Metastasis From Periampullary or Pancreatic Cancer: A High Portal Venous CTC Count Predicts Liver MetastasesYu Wen Tien, Hsun-Chuan Kuo, Be-Ing Ho, et al.
Science Translational Medicine|March 4, 2021
Characterization of initial key steps of IL-17 receptor B oncogenic signaling for targeted therapy of pancreatic cancerHeng-Hsiung Wu, Lung-Hung Tsai, Chun-Kai Huang, et al.
International Journal of Radiation Oncology, Biology, Physics|March 23, 2011
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II studyHui-Ju Ch'ang, Yu-Lin Lin, Hsiu-Po Wang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 3, 2014
High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infectionJyh-Chin Yang, Chun-Jung Lin, Hong-Long Wang, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Nature Communications|February 13, 2026
PanMETAI - a high performance tabular foundation model for accurate pancreatic cancer diagnosis via NMR metabolomicsDan-Ni Wu, Joey Jen, Erickson Fajiculay, et al.
Journal of Gastroenterology and Hepatology|May 18, 2006
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancerHui-Ju Ch'ang, Chuan-Cheng Wang, Ann-Lii Cheng, et al.
American Journal of Cancer Research|January 22, 2019
Cellular 5-hydroxylmethylcytosine content determines tumorigenic potential and prognosis of pancreatic ductal adenocarcinomaYi-Lng Chen, Chun-Mei Hu, Jeh-Ting Hsu, et al.
Cancer Chemotherapy and Pharmacology|March 26, 2009
Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancerHui-Ju Ch'ang, Chin-Lun Huang, Hsiu-Po Wang, et al.
Clinical Chemistry|February 11, 2016
Clinical Significance of Circulating Tumor Microemboli as a Prognostic Marker in Patients with Pancreatic Ductal AdenocarcinomaMing-Chu Chang, Yu-Ting Chang, Jia-Yang Chen, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|November 15, 2023
Oncogenic KRAS, Mucin 4, and Activin A-Mediated Fibroblast Activation Cooperate for PanIN InitiationChun-Mei Hu, Chien-Chang Huang, Min-Fen Hsu, et al.
Medicine|April 22, 2016
A High Circulating Tumor Cell Count in Portal Vein Predicts Liver Metastasis From Periampullary or Pancreatic Cancer: A High Portal Venous CTC Count Predicts Liver MetastasesYu Wen Tien, Hsun-Chuan Kuo, Be-Ing Ho, et al.
Science Translational Medicine|March 4, 2021
Characterization of initial key steps of IL-17 receptor B oncogenic signaling for targeted therapy of pancreatic cancerHeng-Hsiung Wu, Lung-Hung Tsai, Chun-Kai Huang, et al.
International Journal of Radiation Oncology, Biology, Physics|March 23, 2011
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II studyHui-Ju Ch'ang, Yu-Lin Lin, Hsiu-Po Wang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 3, 2014
High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infectionJyh-Chin Yang, Chun-Jung Lin, Hong-Long Wang, et al.
Pageof 8